Back to Journals » International Journal of Nanomedicine » Volume 13 » T-NANO 2014 Abstracts

Liposome encapsulation of doxorubicin and celecoxib in combination inhibits progression of human skin cancer cells

Authors Singh S

Received 14 October 2016

Accepted for publication 30 October 2016

Published 15 March 2018 Volume 2018:13(T-NANO 2014 Abstracts) Pages 11—13


Checked for plagiarism Yes

Review by Single-blind

Peer reviewer comments 3

Editor who approved publication: Dr Lei Yang

Sanjay Singh

Institute of Life Sciences, School of Science and Technology, Ahmedabad University, Ahmedabad, Gujarat, India

Abstract: Therapeutic agents aimed at inhibiting a single molecular target have not been successful in cancer therapy, but rather they impart resistance. However, multi-target inhibitors have shown promising results in circumventing the development of resistance and inducing apoptosis in cancer cells/tissues. In this study, we encapsulated doxorubicin and celecoxib in a single liposome at a ratio of 1:10. These dual drug-encapsulated liposomes showed excellent anticancer activity compared to individually encapsulated liposomes. The expression of key proteins such as AKT and COX-2 was suppressed, which suggests that doxorubicin and celecoxib synergistically inhibit multiple key signaling pathways.

Keywords: drug delivery, nanoliposomes, nanomedicines, cancer nanotechnology

Creative Commons License This work is published and licensed by Dove Medical Press Limited. The full terms of this license are available at and incorporate the Creative Commons Attribution - Non Commercial (unported, v3.0) License. By accessing the work you hereby accept the Terms. Non-commercial uses of the work are permitted without any further permission from Dove Medical Press Limited, provided the work is properly attributed. For permission for commercial use of this work, please see paragraphs 4.2 and 5 of our Terms.

Download Article [PDF]  View Full Text [HTML][Machine readable]